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1,25 OH Vitamin D Mediated Hypercalcemia in a Patient With Malignancy Without Lymphoma
Katie Mastoris DO, Sarah Park DO and Vasudev Magaji MD

Division of Endocrinology, Department of Medicine, Lehigh Valley Health Network, Allentown, Pennsylvania
ABSTRACT:
Objective: Describe an unusual case of 1,25 OH vitamin D
mediated hypercalcemia in a patient with colonic adenocarcinoma
and mesothelioma.
Methods: Case Report.
Case: A 62-year-old male presented with constipation and left
abdominal pain of 1-month duration. Abdominal CT revealed rectal
thickening concerning for cancer with metastatic lymphadenopathy,
metastatic peritoneal lesion and a 20cm liver mass. Biopsy
of sigmoid colon showed invasive moderately differentiated
adenocarcinoma. Four months prior, his labs were calcium 9.8mg/
dL (8.2-10.4 mg/dL), albumin 4.6gm/dL (3.5-5.0g/dL), eGFR 96mL/
min/1.73m2 with normal BUN and creatinine. At presentation his
labs were calcium 10.5mg/dL, albumin 4.2gm/dL, BUN 29mg/dL
(10-26mg/dl), creatinine 1.59mg/dL (0.7-1.50 mg/dL) and eGFR
46. During subsequent hospitalization for right leg cellulitis, he
had calcium 11.9mg/dL and ionized calcium 6.45mg/dL with low
albumin 3.4gm/dL. He developed sepsis and due to concern for
liver abscess the liver mass was biopsied.  Pathology showed high
grade malignant neoplasm consistent with epithelioid mesothelioma.
Septicemia and renal failure requiring dialysis complicated his
course.
Hypercalcemia workup showed no evidence of osteolytic lesions
on imaging, normal 25 OH vitamin D 46ng/mL (30-100ng/mL), low
intact parathyroid hormone (PTH) 12pg/mL (14-72 pg/mL), normal
parathyroid hormone related protein (PTHrP) at 1.1pmol/L (<2.0
pmol/L) and absent monoclonal proteins on serum and urine protein
electrophoresis. 1,25 OH vitamin D was high on two samples at 95
and 77pg/mL (18-64pg/mL).
The patient’s calcium gradually improved with administration of
pamidronate to 7.0mg/dL with an albumin of 1.9gm/dL and a
corrected calcium 8.7mg/dL. Despite being on 3 vasopressors,
antibiotics and continuous renal replacement therapy, his condition
deteriorated and patient died on comfort measures.
Discussion: Hypercalcemia resulting from calcium homeostasis
imbalance is seen in one third of malignancies and is a poor
prognostic factor. Solid malignancies cause hypercalcemia from
high PTHrP and less commonly from osteolytic cytokines. Excessive
1,25 OH vitamin D seen mostly in lymphoma causes hypercalcemia
by 1-hydroxylation of 25 OH vitamin D. This mechanism has also
been reported in dysgerminoma, myofibroblastic tumour and
gastrointestinal stromal tumours. This patient had hypercalcemia
from high 1,25 OH vitamin D with mesothelioma and colon cancer.
Ex vivo upregulation of 1-hydroxylase in colon cancer has been
described but there are no colon cancer case reports of 1,25 OH
vitamin D mediated hypercalcemia. Hypercalcemia in mesothelemia
from high 1,25 OH vitamin D with calcium normalization following
resection has been reported. We could not establish which
malignancy caused elevation of 1,25 OH vitamin D in this patient.
Conclusion: Elevated 1,25 OH vitamin D could be a
hypercalcemia etiology in non lymphoma malignancies and needs
to be considered when work up for elevated PTHrP and osteolytic
hypercalcemia is negative.

INTRODUCTION:
Hypercalemia is one of the most common endocrine and
electrolyte derangements seen in malignancies.  Paraneoplastic
mechanisms leading to hypercalcemia include tumor production
of parathyroid hormone related protein (PTHrP), osteolytic
bone lesions, ectopic parathyroid hormone (PTH) production
or elevated 1,25 OH vitamin D levels through activation of
an extrarenal 1-alpha-hydroxylase. Hypercalcemia from
elevated 1,25 OH vitamin D is commonly seen in patients with
lymphoma.1  We report a case of 1,25 OH vitamin D mediated
hypercalcemia in a patient with two primary malignancies:
adenocarcinoma of the rectum and epitheloid mesothelioma.  

CASE PRESENTATION:
• A 62-year-old male presented to his primary care physician’s
office with 1 month duration of difficulty moving bowels,
bloating, gas, and abdominal pain.   
• Abdominal CT revealed rectal thickening concerning for cancer
with metastatic lymphadenopathy, metastatic peritoneal lesion
and a 20cm liver mass (Figure 1) (Figure 2).
• Biopsy of sigmoid colon showed invasive moderately
differentiated adenocarcinoma (Figure 3).
• Routine laboratory evaluation at this visit reported elevated
calcium level (Table 1).   
• Five days following colonoscopy and biopsy, the patient
presented to the emergency department with a right lower
extremity cellulitis leading to hospitalization for IV antibiotics.  
• Sepsis developed, the patient deteriorated, and due to concern
for liver abscess the liver mass was biopsied.  Pathology
showed high grade malignant neoplasm consistent with
epithelioid mesothelioma (Figure 4).
• During his hospitalization, calcium levels rose (Table 1) and
work up for the etiology of hypercalcemia began (Table 2).  
There was no evidence of osteolytics lesions on imaging,
serum and urine electrophoresis were negative, thyroid
stimulating hormone was within normal limits, no evidence
of granulomatous disease, no evidence of granulomatous
infection.
• Administration pamidronate brought calcium level down within
normal range.
• Despite being on three vasopressors, antibiotics and
continuous renal replacement therapy, his condition
deteriorated and patient died on comfort measures.

DISCUSSION:

TABLE 1.
July
10
Calcium (8.2-10.4 mg/dL)
Albumin (3.5-5.0g/dL)
Ionized Calcium (4.6-5.4 mg/dL)
eGFR (>60mL/min/1.73m2)
BUN (10-26mg/dl)
Creatinine (0.7-1.50 mg/dL)

At Presentation
October 22

9.8
4.6
96
19
0.79

TABLE 2.
Vitamin D, 25 OH total (30-100ng/mL)
Vitamin D, 1,25-Dihydroxy (18-64pg/mL)
Intact PTH (14-72 pg/mL)
PTHrP (<2.0 pmol/L)

1

46
95 and 77
12
1.1

10.5
4.2
46
29
1.59

Hospitalization
October 31

Administration of
Pamidronate

11.9 (corrected - 12.4) 7.0 (corrected 8.7)
3.4
1.9
6.45
36
14
79
89
1.95
4.31

Table 1: Routine laboratory evaluation
reported elevated calcium level with diagnosis
of moderately differentiated adenocarcinoma
of the sigmoid colon and epitheloid
mesothelioma.
Table 2: Hypercalcemia workup showed no
evidence of osteolytic lesions on imaging,
normal 25 OH vitamin D, low intact PTH,
normal PTHrP and absent monoclonal proteins
on serum and urine protein electrophoresis.
1,25 OH vitamin D was high on two samples.

Our patient had excessive 1,25 OH vitamin D producing hypercalcemia as evident by normal PTHrP, lack of
osteolytic lesions, low PTH and elevated 1,25 OH vitamin D.  
Hypercalcemia resulting from calcium homeostasis imbalance is seen in one third of malignancies
commonly through increased synthesis of PTHrP or metastatic osteolytic bone lesions. 1,25 OH vitamin
elevation causes hypercalcemia by increased vitamin D absorption. Elevated 1,25 OH vitamin D mediated
hypercalcemia has been established in granulomatous diseases and lymphomas.  This mechanism occurs
through elevated extra renal hydroxylation of 25 OH vitamin D.  Extra-renal 1-hydroxylase was found in
1
tumor adjacent tissue macrophages and is resistant to normal feedback controls leading to uncontrolled
hypercalcemia.
There are very few case reports identifying elevations of 1,25 OH vitamin D causing hypercalcemia in
other malignancies. Among these neoplasms, dysgerminomas of ovary leading to hypercalcemia have
been reported in twelve patients.2  Resection of the dygerminoma resulted in normalization of  serum
calcium and 1,25 OH vitamin D.2  A case of inflammatory myofibroblastic tumor on surgical pathology
showing abundant macrophage infiltration has been described to be associated with hypercalcemia with
1,25 OH vitamin D elevation.3 Abundant mRNA encoding for 1-alpha-hydroxylase in this tumoral tissue
was demonstrated.3
A patient with gastrointestinal stromal tumour with 1,25 OH vitamin D associated hypercalcemia who
transiently responded to tyrosine kinase inhibitor and bisphosphonates has been reported.4  Similar
to our patient, a patient with pleural mesothelioma had elevated calcium from this mechanism.5  
Pleural mesothelioma resection resulted in normalization of calcium and 1,25 OH vitamin D.5  Ex vivo
upregulation of mRNA encoding for 1-hydroxylase has been described in colon cancer6,7 but there are no
colon cancer case reports of 1,25 OH vitamin D mediated hypercalcemia. Due to the patients underlying
septicemia and deterioration, we could not establish which malignancy caused elevation of 1,25 OH
vitamin D in this patient. However this case reports the rare occurrence of 1,25 OH vitamin D mediated
hypercalcemia in patient with malignancy without lymphoma.

2

Figure 1: Sagittal view of CT scan abdomen and pelvis with contrast demonstrating
circumferential rectal wall thickening suggesting a mass measuring up to 11.8mm in thickness.
Figure 2: CT scan abdomen and pelvis with IV contrast demonstrating a large 15.7cm by
8.4cm mass which appears to be centered within the left lobe of the liver but is exophytic,
abutting the pancreas and stomach but not appearing to originate in either of these organs.

CONCLUSION:
Elevated 1,25 OH vitamin D could be a hypercalcemia etiology in non lymphoma malignancies.  This
case shows two different malignancies associated with this mechanism, neither of which has been well
reported in the literature.  Future investigation should be considered when work up for elevated PTHrP and
osteolytic hypercalcemia is negative.
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Figure 3: Sigmoid biopsy in formalin showing invasive moderately differentiated
adenocarcinoma. Depth of involvement cannot be determined.
Figure 4: Liver core biopsy showing high grade malignant neoplasm consistent with epithelioid
mesothelioma. Immunoperoxidase stain for inhibin, CAM 5.2, CK7, calretinin, WT1 were
positive. This malignant neoplasm is histologically distinct from his rectal adenocarcinoma and
represents a synchronous secondary primary neoplasm.
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